Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE

Ambrose, 2016, Differences in disease phenotype and severity in SLE across age groups, Lupus, 25, 1542, 10.1177/0961203316644333 Hersh, 2010, Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus, Arthritis Care Res (Hoboken), 62, 1152, 10.1002/acr.20179 Bakshi, 2018, Unmet needs in the pathogenesis and treatment of systemic lupus erythematosus, Clin Rev Allergy Immun, 55, 352, 10.1007/s12016-017-8640-5 Bernatsky, 2006, Mortality in systemic lupus erythematosus, Arthritis Rheumatism, 54, 2550, 10.1002/art.21955 Nossent, 2007, Current causes of death in systemic lupus erythematosus in Europe, 2000—2004: relation to disease activity and damage accrual, Lupus, 16, 309, 10.1177/0961203307077987 Quinlan, 2015, The vascular phenotype of children with systemic lupus erythematosus, Pediatr Nephrol, 30, 1307, 10.1007/s00467-015-3059-9 Hersh, 2010, Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus, Arthritis Care Res, 62, 1152, 10.1002/acr.20179 McMahon, 2009, Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus, Arthritis Rheumatism, 60, 2428, 10.1002/art.24677 Tyrrell, 2007, Predictors of lipid abnormalities in children with new-onset systemic lupus erythematosus, J Rheumatol, 34, 2112 Posadas-Romero, 2004, High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus, Arthritis Rheumatism, 50, 160, 10.1002/art.11472 Ardoin, 2007, Review: management of dyslipidemia in children and adolescents with systemic lupus erythematosus, Lupus, 16, 618, 10.1177/0961203307079566 Borba, 2000, Chylomicron metabolism is markedly altered in systemic lupus erythematosus, Arthritis Rheumatism, 43, 1033, 10.1002/1529-0131(200005)43:5<1033::AID-ANR11>3.0.CO;2-B Schanberg, 2009, Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort, Arthritis Rheum, 60, 1496, 10.1002/art.24469 Barsalou, 2013, Cardiovascular risk in pediatric-onset rheumatological diseases, Arthritis Res Ther, 15, 12, 10.1186/ar4212 Cairoli, 2012, Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect, Lupus, 21, 1178, 10.1177/0961203312450084 Yu, 2015, Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study, Atherosclerosis, 243, 11, 10.1016/j.atherosclerosis.2015.08.030 Ruiz-Limon, 2015, Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment, Ann Rheum Dis, 74, 1450, 10.1136/annrheumdis-2013-204351 Ardoin, 2014, Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein, Ann Rheum Dis, 73, 557, 10.1136/annrheumdis-2012-202315 Petri, 2011, Lupus Atherosclerosis Prevention Study (LAPS), 70, 760 Schanberg, 2012, Use of atorvastatin in systemic lupus erythematosus in children and adolescents, Arthritis Rheum, 64, 285, 10.1002/art.30645 van Vollenhoven, 2015, Remission in SLE: closing in on the target, Ann Rheum Dis, 74, 2103, 10.1136/annrheumdis-2015-208231 Isenberg, 2016, Why, why, why de-lupus (does so badly in clinical trials), Expert Rev Clin Immunol, 12, 95, 10.1586/1744666X.2016.1112270 McQueen, 2008, Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study, Lancet, 372, 224, 10.1016/S0140-6736(08)61076-4 Walldius, 2001, High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study, Lancet, 358, 2026, 10.1016/S0140-6736(01)07098-2 Hochberg, 1997, Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum, 40, 1725, 10.1002/art.1780400928 Petri, 2012, Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus, Arthritis Rheum, 64, 2677, 10.1002/art.34473 Yee, 2011, The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients, Rheumatology, 50, 982, 10.1093/rheumatology/keq376 Franklyn, 2016, Definition and initial validation of a lupus low disease activity state (LLDAS), Ann Rheum Dis, 75, 1615, 10.1136/annrheumdis-2015-207726 Novikova, 2016, The effects of rituximab on lipids, arterial stiffness, and carotid intima-media thickness in rheumatoid arthritis, J Korean Med Sci, 31, 202, 10.3346/jkms.2016.31.2.202 Soininen, 2015, Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics, Circulation, 8, 192 Metsalu, 2015, ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap, Nucleic Acids Res, 43, W566, 10.1093/nar/gkv468 Core Team, 2014 MKaQ, 2018 Dobiasova, 2004, Atherogenic index of plasma Log(Triglycerides/HDL-cholesterol: theoretical and practical implications, Clin Chem, 50, 1113, 10.1373/clinchem.2004.033175 Smith, 2016, Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque, Sci Immunol, 1, 10.1126/sciimmunol.aah4081 Lawler, 2016, Circulating N-linked glycoprotein acetyls and longitudinal mortality risk, Circ Res, 118, 1106, 10.1161/CIRCRESAHA.115.308078 Holmes, 2018, Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke, J Am Coll Cardiol, 71, 620, 10.1016/j.jacc.2017.12.006 Wurtz, 2016, Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase, J Am Coll Cardiol, 67, 1200, 10.1016/j.jacc.2015.12.060 Kofink, 2017, Statin effects on metabolic profiles: data from the PREVEND IT (prevention of renal and vascular end-stage disease intervention trial), Circulat-Cardiovascular Gen, 10, 9 Sliz, 2018, Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment, Circulation, 138, 2499, 10.1161/CIRCULATIONAHA.118.034942 Bogl, 2013, Association between habitual dietary intake and lipoprotein subclass profile in healthy young adults, Nutr Metabol Cardiovasc Dis, 23, 1071, 10.1016/j.numecd.2012.11.007 Hahn, 2007, The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia, J Autoimmun, 28, 69, 10.1016/j.jaut.2007.02.004 Fernandez, 2019, Single-cell immune landscape of human atherosclerotic plaques, Nat Med, 25, 1576, 10.1038/s41591-019-0590-4 Cochain, 2018, Single-cell RNA-seq reveals the transcriptional landscape and heterogeneity of aortic macrophages in murine atherosclerosis, Circ Res, 122, 1661, 10.1161/CIRCRESAHA.117.312509 El-Sherbiny, 2018, A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features, Sci Rep, 8, 11 Sanin, 2017, Dyslipidemias and cardiovascular prevention: tailoring treatment according to lipid phenotype, Curr Cardiol Rep, 19, 13, 10.1007/s11886-017-0869-3 Kettunen, 2016, Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA, Nat Commun, 7, 11122, 10.1038/ncomms11122 Ohukainen, 2020, Data-driven multivariate population subgrouping via lipoprotein phenotypes <em>versus</em>apolipoprotein B in the risk assessment of coronary heart disease, Atherosclerosis, 294, 10, 10.1016/j.atherosclerosis.2019.12.009 Juonala, 2008, Childhood levels of serum Apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood, J Am Coll Cardiol, 52, 293, 10.1016/j.jacc.2008.03.054 Machado, 2017, Lipid profile among girls with systemic lupus erythematosus, Rheumatol Int, 37, 43, 10.1007/s00296-015-3393-z Kwankaew, 2015, Apolipoprotein B as an independent predictor of arterial stiffness in systemic lupus erythematosus patients, Int J Rheumatic Dis, 18, 447, 10.1111/1756-185X.12384 Schmidt, 2008, ApoB/apoA-I ratio is related to femoral artery plaques in 64-year-old women also in cases with low LDL cholesterol, Atherosclerosis, 196, 817, 10.1016/j.atherosclerosis.2007.01.017 Morrison, 2012, Determinants of ApoB, ApoA1, and the ApoB/ApoA1 ratio in healthy schoolgirls, prospectively studied from mean ages 10 to 19 years: the Cincinnati national growth and health study, Metabolism-Clin Exper, 61, 1377, 10.1016/j.metabol.2012.02.014 William, 1971, Serum cholesterol, lipoproteins, and the risk of coronary heart disease, Ann Intern Med, 74, 1, 10.7326/0003-4819-74-1-1 Cochain, 2016, Protective and pathogenic roles of CD8(+) T cells in atherosclerosis, Basic Res Cardiol, 111, 10, 10.1007/s00395-016-0589-7 van Duijn, 2019, CD8(+) T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4(+) T-cell responses, Cardiovasc Res, 115, 729, 10.1093/cvr/cvy261 Tabas, 2017, Monocyte-macrophages and T cells in atherosclerosis, Immunity, 47, 621, 10.1016/j.immuni.2017.09.008 Padgett LE, Dinh HQ, Wu R, Gaddis DE, Araujo DJ, Winkels H, et al. Naive CD8+T Cells expressing CD95 increase human cardiovascular disease severity. Arterioscler Thromb Vasc Biol. 0(0):ATVBAHA.120.315106. Sherer, 2006, Mechanisms of disease: atherosclerosis in autoimmune diseases, Nat Clin Practice Rheumatol, 2, 99, 10.1038/ncprheum0092 Kahlenberg, 2011, The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus, Arthritis Res Ther, 13, 203, 10.1186/ar3264 Chen, 2019, Type-I interferons in atherosclerosis, J Exp Med, 217, 10.1084/jem.20190459 McLaren, 2009, Interferon gamma: a master regulator of atherosclerosis, Cytokine Growth Factor Rev, 20, 125, 10.1016/j.cytogfr.2008.11.003 Somers, 2012, Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients, PLoS One, 7, 8, 10.1371/journal.pone.0037000 Denny, 2007, Inteirferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis, Blood, 110, 2907, 10.1182/blood-2007-05-089086 Knight, 2013, Cardiovascular disease in lupus: insights and updates, Curr Opin Rheumatol, 25, 597, 10.1097/BOR.0b013e328363eba3 Blaszczyk, 2016, The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses, Cytokine Growth Factor Rev, 29, 71, 10.1016/j.cytogfr.2016.02.010 Szelag, 2016, Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease, Oncotarget, 7, 48788, 10.18632/oncotarget.9195 Niessner, 2006, Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha, Circulation, 114, 2482, 10.1161/CIRCULATIONAHA.106.642801 Feng, 2017, Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus, Lupus, 26, 62, 10.1177/0961203316651738 Chasset, 2018, Targeting interferons and their pathways in systemic lupus erythematosus, Autoimmun Rev, 17, 44, 10.1016/j.autrev.2017.11.009 Murphy, 2019, New therapies for systemic lupus erythematosus — past imperfect, future tense, Nat Rev Rheumatol, 15, 403, 10.1038/s41584-019-0235-5 Kattoor, 2017, Oxidative stress in atherosclerosis, Curr Atheroscler Rep, 19, 42, 10.1007/s11883-017-0678-6